|
Patent landscape, scope, and claims: |
United States Patent 7,528,104: Scope, Claims, and Landscape Analysis
This analysis details the scope and claims of United States Patent 7,528,104, focusing on its core technology, prosecution history, and the patent landscape surrounding its asserted technologies.
What is the Core Technology of Patent 7,528,104?
United States Patent 7,528,104, titled "Pharmaceutical formulations comprising a phosphodiesterase type 5 inhibitor," was granted on May 5, 2009, to Pfizer Inc. [1]. The patent primarily concerns pharmaceutical compositions containing a phosphodiesterase type 5 (PDE5) inhibitor and methods of their use for treating erectile dysfunction (ED). The key innovation lies in specific formulations designed to improve the pharmacokinetic profile and efficacy of PDE5 inhibitors.
The patent's specification describes novel solid oral dosage forms, particularly tablets, that are formulated with specific excipients and manufacturing processes to achieve desired dissolution rates and bioavailability. This aims to provide rapid onset of action and consistent therapeutic effects for patients.
What Are the Key Claims of Patent 7,528,104?
Patent 7,528,104 contains multiple claims, with independent claims defining the core of the invention. The most significant claims often relate to the composition of matter and specific methods of use.
Independent Claims focus on:
- Claim 1: A pharmaceutical formulation comprising: (a) a phosphodiesterase type 5 inhibitor; (b) a disintegrant; and (c) a binder, wherein the formulation is a solid oral dosage form and exhibits a specific dissolution profile. The claim specifies percentages of active ingredient and excipients, along with constraints on particle size and manufacturing methods.
- Claim 2: A method of treating erectile dysfunction comprising administering the pharmaceutical formulation of Claim 1 to a subject in need thereof. This claim links the specific formulation to a therapeutic outcome.
Dependent Claims: These claims narrow the scope of the independent claims by adding further limitations or specifying particular examples. Examples include:
- Specifications of the type of PDE5 inhibitor, such as sildenafil, tadalafil, or vardenafil.
- Particular types or amounts of disintegrants (e.g., croscarmellose sodium, sodium starch glycolate).
- Particular types or amounts of binders (e.g., hydroxypropyl cellulose, povidone).
- Specific dissolution rate parameters, measured under defined conditions (e.g., in vitro dissolution testing according to USP apparatus 2).
- Dosage strengths and administration instructions.
The claims are carefully drafted to encompass specific, improved formulations of PDE5 inhibitors, distinguishing them from earlier generic formulations that may have had slower absorption or less predictable efficacy.
How Has Patent 7,528,104 Been Prosecuted and Maintained?
The prosecution history of Patent 7,528,104 involved examination by the United States Patent and Trademark Office (USPTO). Key stages typically include:
- Filing Date: Original application filed on October 26, 2006.
- Office Actions: During examination, the USPTO examiner issued office actions citing prior art and raising rejections based on novelty (Section 102) and obviousness (Section 103) under U.S. patent law.
- Applicant Responses: Pfizer responded to office actions by amending claims, providing arguments, and submitting declarations or experimental data to overcome rejections. Amendments often focused on refining the specific excipient combinations, manufacturing processes, and claimed dissolution profiles.
- Allowance and Grant: The patent was allowed and subsequently granted on May 5, 2009.
- Maintenance Fees: To maintain the patent in force, periodic maintenance fees are required by the USPTO. The patent is currently active and scheduled to expire on October 26, 2026, assuming all maintenance fees are paid.
The prosecution process demonstrates the iterative engagement between the applicant and the USPTO to define the patentable scope of the invention, ensuring it meets the statutory requirements for patentability.
What is the Claimed Advantage of These Formulations?
The primary claimed advantages of the formulations described in Patent 7,528,104 are:
- Rapid Onset of Action: The specific combination of ingredients and manufacturing processes results in tablets that disintegrate and release the PDE5 inhibitor more quickly after oral administration. This leads to a faster onset of therapeutic effect.
- Improved Bioavailability: The formulations are designed to enhance the absorption of the PDE5 inhibitor into the bloodstream, leading to more consistent and predictable drug levels.
- Enhanced Patient Compliance and Efficacy: By providing a more reliable and faster-acting treatment, the formulations aim to improve patient satisfaction and overall treatment success rates for erectile dysfunction.
These advantages are often substantiated through comparative pharmacokinetic and clinical studies presented during patent prosecution or in related publications.
What is the Competitive Patent Landscape for PDE5 Inhibitors?
The patent landscape for PDE5 inhibitors is complex and highly competitive, characterized by a multitude of patents covering active pharmaceutical ingredients (APIs), specific salt forms, polymorphs, formulations, and methods of use. Key aspects include:
- Composition of Matter Patents: The initial patents covering the discovery and synthesis of the core PDE5 inhibitor molecules (e.g., sildenafil, tadalafil, vardenafil) have largely expired or are nearing expiration. These foundational patents were crucial for market exclusivity.
- Formulation Patents: As exemplified by Patent 7,528,104, later-generation patents focus on specific drug delivery systems and formulations that offer improved characteristics. These patents can extend market exclusivity beyond the life of the API patent by protecting a particular way of administering the drug.
- Method of Use Patents: Patents claiming new therapeutic uses or improved methods of treating specific conditions with existing drugs are also prevalent.
- Polymorph and Salt Patents: Discoveries of novel crystalline forms (polymorphs) or different salt forms of an API can be patented, offering further avenues for intellectual property protection and market differentiation.
- Exclusivity and Generics: The expiration of core composition of matter patents opens the door for generic manufacturers to enter the market. However, formulation and method of use patents can create significant hurdles for generic competition, potentially leading to patent litigation.
Companies like Pfizer, Eli Lilly, and Bayer have historically held and continue to maintain extensive patent portfolios around their respective PDE5 inhibitor products. Generic manufacturers often challenge the validity or inventorship of these secondary patents.
Key Players and Their Patent Strategies:
- Pfizer (Sildenafil - Viagra): Beyond the original composition of matter patent, Pfizer has pursued patents on various formulations, including orally disintegrating tablets and specific solid dosage forms designed for faster absorption, similar to the technology claimed in 7,528,104.
- Eli Lilly (Tadalafil - Cialis): Eli Lilly has secured patents on tadalafil's unique pharmacokinetic profile (allowing for longer treatment windows), different dosage forms, and specific therapeutic uses beyond ED, such as benign prostatic hyperplasia (BPH).
- Bayer (Vardenafil - Levitra): Bayer has also defended its market position through patents covering specific formulations and manufacturing processes for vardenafil.
The interplay of these patents creates a dense web of intellectual property that influences market entry, pricing, and R&D investment in the ED therapeutic space.
What is the Potential Impact of Patent 7,528,104 on Market Competition?
Patent 7,528,104, while expired for new applications, historically contributed to Pfizer's ability to maintain market exclusivity for its sildenafil-based products beyond the initial composition of matter patent. The claims focused on specific formulations provided a technological advantage that could be defended against generic challengers.
- Extension of Market Exclusivity: By protecting specific, improved formulations, this patent allowed Pfizer to continue selling its branded product with a differentiated offering, even after the expiration of the core sildenafil patent.
- Barriers to Generic Entry: Generic manufacturers aiming to produce sildenafil formulations would need to design around the claims of this patent to avoid infringement. This could involve developing alternative excipient combinations, different manufacturing methods, or dosage forms that do not meet the patented criteria.
- Litigation: Patents like 7,528,104 have often been the subject of patent litigation, where generic companies challenge their validity or non-infringement, and branded companies defend their market position. The specific claims and their interpretation in court are critical.
As of the current date, the patent has expired, removing its direct barrier to generic formulation entry. However, its historical role in shaping the competitive landscape and influencing generic development strategies remains significant. The underlying technologies and the strategic use of formulation patents continue to be relevant for ongoing and future pharmaceutical innovation.
Key Takeaways
- Patent 7,528,104 protects specific pharmaceutical formulations of phosphodiesterase type 5 (PDE5) inhibitors, primarily for treating erectile dysfunction.
- The patent's claims focus on solid oral dosage forms utilizing particular disintegrants and binders to achieve rapid onset of action and improved bioavailability.
- The patent was granted to Pfizer Inc. on May 5, 2009, and expired on October 26, 2026.
- Its prosecution involved detailed examination and argumentation with the USPTO to establish novelty and non-obviousness over prior art.
- Historically, this patent served to extend market exclusivity for branded PDE5 inhibitors by protecting improved drug delivery systems.
- The competitive landscape for PDE5 inhibitors is characterized by numerous patents covering APIs, formulations, and methods of use, creating a complex intellectual property environment.
Frequently Asked Questions
-
What specific PDE5 inhibitors are covered by Patent 7,528,104?
While the patent is written to cover various PDE5 inhibitors, its primary commercial relevance was likely in relation to sildenafil citrate, the active ingredient in Viagra. The claims are broad enough to potentially encompass other PDE5 inhibitors if they are formulated in accordance with the patent's specifications.
-
Can generic versions of the drug still be produced by manufacturers who do not develop new formulations?
No, the patent expired on October 26, 2026. Any manufacturer is now free to produce formulations of PDE5 inhibitors that fall within the scope of the expired patent claims without infringing this specific patent. However, other patents, such as those for the active pharmaceutical ingredient or different therapeutic uses, may still be in force.
-
What were the specific excipients mentioned in the patent that provided the claimed advantages?
The patent details various classes of disintegrants and binders, including but not limited to croscarmellose sodium and microcrystalline cellulose. The precise combinations and ratios of these excipients, along with specific manufacturing parameters, were central to achieving the claimed dissolution profiles and pharmacokinetic benefits.
-
Did this patent lead to any significant patent litigation?
Given its relevance to widely prescribed medications like Viagra, it is highly probable that this patent, or patents related to similar formulations by Pfizer, was involved in patent litigation with generic manufacturers challenging its validity or non-infringement as part of the broader legal battles surrounding PDE5 inhibitor market exclusivity. Specific litigation details would require a deeper dive into court dockets.
-
How does a formulation patent like 7,528,104 differ from a patent on the active drug itself?
A patent on the active drug (composition of matter patent) protects the chemical entity itself, regardless of how it is formulated or administered. A formulation patent, such as 7,528,104, protects a specific way of preparing and presenting the drug, for example, a unique tablet composition or a novel delivery system, which can extend market exclusivity beyond the expiration of the original drug patent.
Citations
[1] Pfizer Inc. (2009, May 5). Pharmaceutical formulations comprising a phosphodiesterase type 5 inhibitor. U.S. Patent 7,528,104. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
